PHAXIAM Therapeutics S.A. - Asset Resilience Ratio

Latest as of June 2024: 3.74%

PHAXIAM Therapeutics S.A. (PHXM) has an Asset Resilience Ratio of 3.74% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PHAXIAM Therapeutics S.A. (PHXM) working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

€1.46 Million

≈ $1.71 Million USD Cash + Short-term Investments

Total Assets

€39.11 Million

≈ $45.72 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2023)

This chart shows how PHAXIAM Therapeutics S.A.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see PHXM total asset value.

Liquid Assets Composition Over Time

This chart breaks down PHAXIAM Therapeutics S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore long-term investment intensity of PHAXIAM Therapeutics S.A. to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€1.46 Million	3.74%
Short-term Investments	€0.00	0%
Total Liquid Assets	€1.46 Million	3.74%

Asset Resilience Insights

Limited Liquidity: PHAXIAM Therapeutics S.A. maintains only 3.74% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

PHAXIAM Therapeutics S.A. Industry Peers by Asset Resilience Ratio

Compare PHAXIAM Therapeutics S.A.'s asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Aurinia Pharmaceuticals Inc NASDAQ:AUPH	Biotechnology	33.23%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%

Annual Asset Resilience Ratio for PHAXIAM Therapeutics S.A. (2016–2023)

The table below shows the annual Asset Resilience Ratio data for PHAXIAM Therapeutics S.A..

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2023-12-31	20.41%	€10.47 Million ≈ $12.25 Million	€51.31 Million ≈ $59.98 Million	-64.35pp
2022-12-31	84.77%	€38.83 Million ≈ $45.40 Million	€45.81 Million ≈ $53.56 Million	+33.58pp
2021-12-31	51.19%	€34.18 Million ≈ $39.96 Million	€66.77 Million ≈ $78.06 Million	-4.10pp
2020-12-31	55.29%	€44.45 Million ≈ $51.97 Million	€80.40 Million ≈ $94.00 Million	-6.45pp
2019-12-31	61.74%	€73.19 Million ≈ $85.56 Million	€118.55 Million ≈ $138.59 Million	-18.32pp
2018-12-31	80.06%	€134.37 Million ≈ $157.09 Million	€167.84 Million ≈ $196.22 Million	-3.66pp
2016-12-31	83.72%	€37.65 Million ≈ $44.01 Million	€44.97 Million ≈ $52.57 Million	--

pp = percentage points

About PHAXIAM Therapeutics S.A.

PA:PHXM France Biotechnology

Market Cap

$1.18 Million

€1.01 Million EUR

Market Cap Rank

#30689 Global

#573 in France

Share Price

€0.10

Change (1 day)

+0.00%

52-Week Range

€0.10 - €0.10

All Time High

€283.83